In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Principia Biopharma, Inc.

http://www.principiabio.com/

Latest From Principia Biopharma, Inc.

BTK Inhibitors Are The Next Big Race In MS

BTK inhibitors are in late-stage development for multiple sclerosis, with Merck KgAA and Sanofi in the lead and Roche and Novartis close behind.

Clinical Trials Business Strategies

Sanofi Maps Out R&D Expectations For 2H 2021

Sanofi has transformed the productivity of its R&D pipeline over the past several years, and late-stage clinical data readouts are expected in the second half of this year for new anticancer drugs, a candidate pemphigus therapy and a COVID-19 vaccine.

Clinical Trials Cancer

Sanofi Upbeat On Itepekimab, Rilzabrutinib And Oral IRAK4 Protein Degrader

Sanofi outlines progress on developing a differentiated R&D pipeline in immunology, including novel ways of addressing COPD, atopic dermatitis and autoimmune disorders.

Immune Disorders Research & Development

Sanofi Grows Clinical Trials During Pandemic With Use Of Inhouse Clinical Supply Chain

Sanofi R&D head John Reed says company has kept 95% of patients on its nearly 400 clinical trials and started 59 studies. Company has also stepped up collaborations and closed acquisitions, integrating employees remotely.

Coronavirus COVID-19 Clinical Trials
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • ADMET
UsernamePublicRestriction

Register